Skip to main content

Table 1 Baseline patient demographics and clinical characteristics

From: Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Demographics or Clinical characteristics Arm I: Axitinib (Continuous) + Pem/Cis Arm II: Axitinib (Modified) + Pem/Cis Arm III: Pem/Cis Alone
  n= 55 n= 58 n= 57
Age, yr, median (range) 62 (30–77) 62 (35–83) 59 (42–76)
Gender, n (%)    
 Male 34 (62) 37 (64) 37 (65)
 Female 21 (38) 21 (36) 20 (35)
Race, n (%)    
 White 39 (71) 49 (84) 45 (79)
 Black 0 1 (2) 0
 Asian 15 (27) 8 (14) 12 (21)
 Other 1 (2) 0 0
Smoking status, n (%)    
 Never smoked 15 (27) 9 (16) 12 (21)
 Smokera 40 (73) 49 (84) 45 (79)
ECOG PS, n (%)    
 0 25 (45) 25 (43) 27 (47)
 1 30 (55) 33 (57) 28 (49)
 Not reported 0 0 2 (4)
Histological classification, n (%)    
 Adenocarcinoma 53 (96) 52 (90) 47 (82)
 Large cell 1 (2) 3 (5) 8 (14)
 Bronchioloalveolar 0 2 (3) 2 (4)
 Other 1 (2) 1 (2) 0
Disease stage at baseline, n (%)    
 Stage IIIB 3 (5) 6 (10) 4 (7)
 Stage IV 46 (84) 50 (86) 52 (91)
 Recurrent 6 (11) 2 (3) 1 (2)
Prior therapy, n (%)    
 Resectionb 14 (25) 12 (21) 16 (28)
 Radiation 11 (20) 7 (12) 8 (14)
  1. Abbreviations: Pem/Cis Pemetrexed/cisplatin, ECOG PS Eastern Cooperative Oncology Group performance status.
  2. aIncluded both active and ex-smokers.
  3. bIncluded partial resection.